Loading
Eribulin lengthened survival by two months compared with dacarbazine in previously treated liposarcoma and leiomyosarcoma, with the entire benefit in liposarcoma, where survival improved by seven months, leading to its approval for that subtype.
Phase 3 trial of 452 patients with advanced liposarcoma or leiomyosarcoma after at least two prior regimens randomised to eribulin or dacarbazine.
Median overall survival was 13.5 versus 11.5 months (hazard ratio 0.77) overall, and 15.6 versus 8.4 months in liposarcoma (hazard ratio 0.51) with no difference in leiomyosarcoma; progression-free survival was similar between arms.
Eribulin is an approved later-line treatment for liposarcoma, one of the few sarcoma drugs with a demonstrated survival benefit.
Shares Eribulin, The Lancet.
Shares Liposarcoma, Dacarbazine.
Shares Dacarbazine, The Lancet.
Shares Liposarcoma, Dacarbazine, Eribulin.
Shares Patrick Schöffski, Liposarcoma.
Shares Liposarcoma, Eribulin.